DiaSorin S.p.A.

DiaSorin S.p.A. is a global biotechnology and diagnostics company specializing in immunodiagnostics, molecular diagnostics, infectious disease testing, endocrinology, oncology, and laboratory automation. Founded in 1968 and headquartered in Saluggia, Italy, DiaSorin develops and manufactures advanced diagnostic solutions used by hospitals, clinical laboratories, and healthcare providers in more than 60 countries.

The company is widely recognized for its LIAISON® immunodiagnostic systems and Simplexa® molecular diagnostic platforms, which provide highly accurate and rapid testing for infectious diseases, autoimmune disorders, vitamin deficiencies, gastrointestinal infections, respiratory diseases, and oncology biomarkers. Following its acquisition of Luminex Corporation, DiaSorin expanded its capabilities in multiplex molecular diagnostics, genomics, and life science technologies.

DiaSorin continuously invests in research and development, laboratory automation, digital diagnostics, and precision medicine to support healthcare professionals with reliable and efficient diagnostic tools. Its manufacturing facilities and innovation centers operate under rigorous international quality standards and comply with regulatory requirements established by the US FDA, European IVDR, ISO 13485, and other global health authorities.

Through continuous innovation and scientific excellence, DiaSorin has established itself as one of the world’s leading providers of specialty diagnostic solutions.